The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Levshin V.F.

N.N. Blokhin National Medical Research Center of Oncology

Epidemiology and prevention of prostate cancer

Authors:

Levshin V.F.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2025;28(7): 111‑118

DOI: 10.17116/profmed202528071111

Read: 609 times

Buy for 300₽
Contact the author
Table of contents

EPIDEMIOLOGY AND PREVENTION OF PROSTATE CANCER
EPIDEMIOLOGY AND PREVENTION OF PROSTATE CANCER

To cite this article:

Levshin VF. Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medicine. 2025;28(7):111‑118. (In Russ.)
https://doi.org/10.17116/profmed202528071111

 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Rationale for the use of non-linear statistical methods in the analysis of rela­tionships between risk factors and fatal events acco­rding to the data of long-term prospective obse­rvation in popu­lation of Russia and the United States of America. Russian Journal of Preventive Medi­cine. 2024;(11):34-39
Features of como­rbidity pathology in young people. Russian Journal of Preventive Medi­cine. 2024;(11):63-69
Gastric cancer: inci­dence, risk factors, screening. Russian Journal of Preventive Medi­cine. 2024;(12):135-139
Risk factors asso­ciated with myopic macu­lopathy in acquired myopia. Russian Annals of Ophthalmology. 2024;(5):35-45
Epidemiology of suicidal beha­vior in children and adolescents worldwide. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11-2):16-26
Comparison of models for prediction of spontaneous preterm birth. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):10-19
Patterns of CAF expression in tumors of the geni­tourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35
Pote­ntial of specialized diet therapy in redu­cing toxic mani­festations in patients with meta­static castration-resistant prostate cancer with bone meta­stases during radionuclide therapy with radium chlo­ride [223Ra]. P.A. Herzen Journal of Onco­logy. 2024;(6):33-41
Stru­ctural and functional features of the main arte­ries of the brain and tumor necrosis factor-alpha in people with chro­nic non-infectious diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):178-184
Clinical and epidemiological characteristics of myasthenia in the Altai region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):198-202
Abstract:

Prostate cancer (PC) is one of the most common malignant neoplasms (MNs) worldwide. The incidence of PC continues to rise in most countries, including Russia. A potential strategy to counter the growing spread of PC is the implementation of evidence-based preventive measures into practical healthcare.

OBJECTIVE

To perform the review and generalization of available data on proven risk factors for the development of prostate cancer and prevention technologies contributing to the realization of incidence reduction opportunities.

MATERIALS AND METHODS

The review presents modern data on the spread and dynamics of PC incidence, proven development risk factors and prevention technologies of PC. The search for publications on this topic was carried out in Google, PubMed, eLibrary, RusMed electronic scientific databases.

RESULTS

The PC incidence rates differ significantly between countries and regions of the world. In Northern Europe, the incidence rates are higher by ten folds than those in South and Central Asia. In Russia, PC ranks first in the structure of MNs incidence of the male population, accounting for 17% of the total MNs incidence of men. Over 10 years (2012—2022), the increase in adjusted incidence rates has amounted to 13.66%. To date, a number of proven modifiable and non-modifiable risk factors for the development of PC has been identified. The following technologies for PC prevention have been developed: elimination or neutralization of risk factors activity; chemical prophylaxis with agents efficacy of which has been confirmed in randomized clinical trials; assessment of individual risk of developing PC; PC screening; anticancer education of target population groups on the possibilities and methods of PC prevention.

CONCLUSION

Only preventive measures can stop the growth and reduce the incidence of prostate cancer. Currently, the opportunities for prevention and reduction of prostate cancer incidence have not been realized. It is necessary to widely implement modern effective technologies of this disease prevention in practical healthcare.

Keywords:

prostate cancer
epidemiology
risk factors
measures and technologies of prevention

Authors:

Levshin V.F.

N.N. Blokhin National Medical Research Center of Oncology

Received:

14.03.2025

Accepted:

03.05.2025

Close metadata

References:

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263.  https://doi.org/10.3322/caac.21834
  2. Gandaglia G, Leni R, Bray F, et al. Epidemiology and Prevention of Prostate Cancer. European Urology Oncology. 2021;4(6):877-892.  https://doi.org/10.1016/j.euo.2021.09.006
  3. Wang L, Lu B, He M, et al. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Frontiers in Public Health. 2022;10:811044. https://doi.org/10.3389/fpubh.2022.811044
  4. Zlokachestvenny’e novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’). Pod red. Kaprina AD, Starinskogo VV, Shaxzadovoj AO. M.: MNIOI im. P.A. Gercena — filial FGBU «NMICz radiologii» Minzdrava Rossii; 2022. (In Russ.).
  5. Smirnov AV, Brusina EB, Magaryll YuA, Gordeeva LA. Epidemiological analysis of prostate cancer risk factors. Russian Journal of Preventive Medicine. 2022;25(8):75-82. (In Russ.). https://doi.org/10.17116/profmed20222508175
  6. Cozzi G, Musi G, Ferro M, et al. Progress in prostate cancer prevention. European Journal of Cancer Prevention. 2022;31(6):554-557.  https://doi.org/10.1097/CEJ.0000000000000745
  7. Ni Raghallaigh H, Eeles R. Genetic predisposition to prostate cancer: an update. Familial Cancer. 2022;21(1):101-114.  https://doi.org/10.1007/s10689-021-00227-3
  8. Vidal AC, Oyekunle T, Feng T, et al. Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology, Biomarkers and Prevention. 2020;29(11):2165-2170. https://doi.org/10.1158/1055-9965.EPI-20-0646
  9. Johnson JR, Mavingire N, Woods-Burnham L, et al. The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men. Nature Reviews. Urology. 2024;21(7):422-432.  https://doi.org/10.1038/s41585-023-00849-5
  10. Conti DV, Darst BF, Moss LC, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics. 2021;53(1):65-75.  https://doi.org/10.1038/s41588-021-00786-2
  11. Oczkowski M, Dziendzikowska K, Pasternak-Winiarska A, et al. Dietary Factors and Prostate Cancer Development, Progression, and Reduction. Nutrients. 2021;13(2):496.  https://doi.org/10.3390/nu13020496
  12. Orlich MJ, Mashchak AD, Jaceldo-Siegl K, et al. Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study-2. American Journal of Clinical Nutrition. 2022;116(2):314-324.  https://doi.org/10.1093/ajcn/nqac093
  13. Chang HJ, Pong YH, Chiang CY, et al. A matched case-control study in Taiwan to evaluate potential risk factors for prostate cancer. Scientific Reports. 2023;13(1):4382. Erratum in: Scientific Reports. 2023;13(1):7594. https://doi.org/10.1038/s41598-023-34567-0
  14. Macke AJ, Petrosyan A. Alcohol and Prostate Cancer: Time to Draw Conclusions. Biomolecules. 2022;12(3):375.  https://doi.org/10.3390/biom12030375
  15. Brookman-May SD, Campi R, Henríquez JDS, et al. Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU). European Urology Focus. 2019; 5(5):756-787.  https://doi.org/10.1016/j.euf.2018.02.007
  16. Carthon B, Sibold HC, Blee S, et al. Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. Oncologist. 2021;26(7):537-548.  https://doi.org/10.1002/onco.13749
  17. Levshin VF, Slepchenko NI. Prevalence of modifiable risk factors for malignant tumors and the level of knowledge of the population about the causes of their development. Russian Journal of Preventive Medicine. 2023;26(8):52-59. (In Russ.). https://doi.org/10.17116/profmed20232608152
  18. Thederan I, Chandrasekar T, Tennstedt P, et al. Poor Adherence to International Cancer Prevention Recommendations Among Patients with Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. European Urology Focus. 2020;6(5):935-940.  https://doi.org/10.1016/j.euf.2019.01.006
  19. Baratedi WM, Tshiamo WB, Mogobe KD, McFarland DM. Barriers to Prostate Cancer Screening by Men in Sub-Saharan Africa: An Integrated Review. Journal of Nursing Scholarship. 2020;52(1):85-94.  https://doi.org/10.1111/jnu.12529
  20. Livingstone TL, Saha S, Bernuzzi F, et al. Accumulation of Sulforaphane and Alliin in Human Prostate Tissue. Nutrients. 2022;14(16):3263. https://doi.org/10.3390/nu14163263
  21. Traka MH, Melchini A, Coode-Bate J, et al. Transcriptional changes in prostate of men on active surveillance after a 12-mo glucoraphanin-rich broccoli intervention-results from the Effect of Sulforaphane on prostate Cancer Prevention (ESCAPE) randomized controlled trial. American Journal of Clinical Nutrition. 2019;109(4):1133-1144. https://doi.org/10.1093/ajcn/nqz012
  22. Zhang Y, Stopsack KH, Song M, et al. Healthy dietary patterns and risk of prostate cancer in men at high genetic risk. International Journal of Cancer. 2024;155(1):71-80.  https://doi.org/10.1002/ijc.34898
  23. Plym A, Zhang Y, Stopsack KH, et al. A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. European Urology. 2023;83(4):343-351.  https://doi.org/10.1016/j.eururo.2022.05.008
  24. Hemani R, Patel I, Inamdar N, et al. Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer. Cancer Prevention Research (Philadelphia, Pa.). 2022;15(2):87-100.  https://doi.org/10.1158/1940-6207.CAPR-21-0242
  25. Joshi SN, Murphy EA, Olaniyi P, Bryant RJ. The multiple effects of aspirin in prostate cancer patients. Cancer Treatment and Research Communications. 2021;26:100267. https://doi.org/10.1016/j.ctarc.2020.100267
  26. Li Y, Cheng X, Zhu JL, et al. Effect of Statins on the Risk of Different Stages of Prostate Cancer: A Meta-Analysis. Urologia Internationalis. 2022;106(9): 869-877.  https://doi.org/10.1159/000518164
  27. Jo JK, Song HK, Heo Y, et al. Risk analysis of metformin use in prostate cancer: a national population-based study. Aging Male. 2023;26(1):2156497. https://doi.org/10.1080/13685538.2022.2156497
  28. Lee MJ, Jayalath VH, Xu W, et al. Association between metformin medication, genetic variation and prostate cancer risk. Prostate Cancer and Prostatic Diseases. 2021;24(1):96-105.  https://doi.org/10.1038/s41391-020-0238-y
  29. Izzo S, Naponelli V, Bettuzzi S. Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention. Nutrients. 2020;12(4):1010. https://doi.org/10.3390/nu12041010
  30. Kapała A, Szlendak M, Motacka E. The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies. Nutrients. 2022; 14(23):5152. https://doi.org/10.3390/nu14235152
  31. Mordecai J, Ullah S, Ahmad I. Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach. International Journal of Molecular Sciences. 2023;24(8):6979. https://doi.org/10.3390/ijms24086979
  32. Ghafouri-Fard S, Shabestari FA, Vaezi S, et al. Emerging impact of quercetin in the treatment of prostate cancer. Biomedicine and Pharmacotherapy. 2021;138:111548. https://doi.org/10.1016/j.biopha.2021.111548
  33. Liu S, Chen J, Wang Y, Xu Y. Effect of dietary antioxidants on the risk of prostate cancer. Systematic review and network meta-analysis. Nutricion Hospitalaria. 2023;40(3):657-667.  https://doi.org/10.20960/nh.04558
  34. Hwang T, Oh H, Lee JA, Kim EJ. Prostate cancer risk prediction based on clinical factors and prostate-specific antigen. BMC Urology. 2023;23(1):100.  https://doi.org/10.1186/s12894-023-01259-w
  35. Bhattu AS, Zappala SM, Parekh DJ, Punnen S. A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. Urology. 2021;148:53-58.  https://doi.org/10.1016/j.urology.2020.11.008
  36. Byrne L, Toland AE. Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening. Urologic Clinics of North America. 2021;48(3):387-399.  https://doi.org/10.1016/j.ucl.2021.03.007
  37. Plym A, Penney KL, Kalia S, et al. Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. Journal of the National Cancer Institute. 2022;114(5):771-774.  https://doi.org/10.1093/jnci/djab058
  38. Hugosson J, Roobol MJ, Månsson M, et al. ERSPC investigators. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology. 2019;76(1):43-51.  https://doi.org/10.1016/j.eururo.2019.02.009
  39. de Vos II, Meertens A, Hogenhout R, et al.; ERSPC Rotterdam Study Group. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer. European Urology. 2023;84(4):426-434.  https://doi.org/10.1016/j.eururo.2023.03.016
  40. van Harten MJ, Roobol MJ, van Leeuwen PJ, et al. Evolution of European prostate cancer screening protocols and summary of ongoing trials. BJU International. 2024;134(1):31-42.  https://doi.org/10.1111/bju.16311
  41. Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. https://doi.org/10.1136/bmj.k3519
  42. Krilaviciute A, Albers P, Lakes J, et al. Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial. International Journal of Cancer. 2023;152(5):854-864.  https://doi.org/10.1002/ijc.34295
  43. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology. 2021;79(2):243-262.  https://doi.org/10.1016/j.eururo.2020.09.042
  44. De Vrieze M, Hübner A, Al-Monajjed R, et al. Das Prostatakarzinom-Screening — aktueller Überblick [Prostate cancer screening-current overview]. Radiologie (Heidelb). 2024;64(6):479-487. Erratum in: Radiologie (Heidelb). 2024;64(7):545.  https://doi.org/10.1007/s00117-024-01312-1
  45. Fazekas T, Shim SR, Basile G, et al. Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis. JAMA Oncology. 2024;10(6):745-754.  https://doi.org/10.1001/jamaoncol.2024.0734
  46. Khalil MIM, Ashour A, Shaala RS, et al. Effect of health belief model-based educational intervention on prostate cancer prevention; knowledge, practices, and intentions. BMC Cancer. 2024;24(1):289.  https://doi.org/10.1186/s12885-024-12044-9
  47. Chiarelli G, Stephens A, Finati M, et al. Adequacy of prostate cancer prevention and screening recommendations provided by an artificial intelligence-powered large language model. International Urology and Nephrology. 2024; 56(8):2589-2595. https://doi.org/10.1007/s11255-024-04009-5
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.